FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380447898> ?p ?o ?g. }

• W4380447898 abstract "Abstract Background and Aims ANCA associated vasculitis (AAV) is a group of systemic autoimmune diseases characterized by inflammation of small and medium sized vessels. The three main types of AAV are granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). Similar pathways are involved mechanisms of disease involving COVID-19 and ANCA-associated vasculitis. For instance, neutrophil extracellular traps (NETs) are induced in both entities. Method We describe 3 cases reports of patients with ANCA associated vasculitis after COVID19. Results Case 1: A 46-year-old female patient was hospitalized in intensive care unit for COVID19 pneumonia. She has fever, cough and dyspnea. A few days before, the SARS-CoV-2 polymerase chain reaction(PCR) was positive on nasopharyngeal swab. She received high flu nasal canula. She presented a pneumo-renal syndrome with intra-alveolar hemorrhage and acute kidney injury. Chest scanner shows lesions on bilateral lung parenchyma, and an acute kidney injury (AKI) on admission. Urinalysis revealed an active sediment with dysmorphic erythrocytes and signifcant proteinuria. Renal function gradually deteriorated. So intermittent hemodialysis treatment was initiated. Serological evaluation showed negative antinuclear antibody, and anti-dsDNA, normal serum complements, and an elevated MPO. In kidney biopsy, pauci-immune necrotizing GN with cellular crescents was detected. The patient received pulse dose corticosteroids and subsequently, she was transitioned to oral prednisone. She underwent 2 sessions of plasmapheresis, which were stopped in the absence of confirmation of pulmonary involvement. She received cyclophosphamide during the hospitalization. While hematuria and proteinuria were persistant in the most recent urinalysis, the sCr level decreased to 159 µmol/L. In addition, she developed adrenal insufficiency after stopping corticosteroid therapy, requiring her to be put on Cortef. Case 2: A 63-year-old female patient with past medical history of hypertension, was hospitalized in intensive care unit for dyspnea and hemoptysis. A few months before, the SARS-CoV-2 polymerase chain reaction(PCR) was positive on nasopharyngeal swab. She received high flu nasal canula (HFNC). At this moment, she had acute kidney injury with a sCr level of 165µmol/L that was not explored. Currently she presented a pneumo-renal syndrome with a rapidly progressive glomerulonephritis and intra-alveolar hemorrhage. Renal function gradually deteriorated and peak sCr level of 308µmol/L. Chest scanner shows ground glass lesions of bilateral lung parenchyma, and hemoglobin at 4.9 g/dL. Urinalysis revealed an active sediment with dysmorphic erythrocytes and signifcant proteinuria. So intermittent hemodialysis treatment was initiated. The patient received pulse dose corticosteroids and subsequently, she was transitioned to oral prednisone. She received cyclophosphamide during the hospitalization. Serological evaluation showed negative antinuclear antibody, and anti-dsDNA, normal serum complements, and an elevated MPO. She underwent 6 sessions of plasmapheresis, for intra-alveolar hemorrhage. There was an improvement in respiratory and renal function Case 3: 57 years old, with a history of functional colopathy, covid infection 1 month before her hospitalization in nephrology department for kidney injury. Currently she presented a pneumo-renal syndrome with a rapidly progressive glomerulonephritis and intra-alveolar hemorrhage. Urinalysis revealed an active sediment with dysmorphic erythrocytes and signifcant proteinuria. Serological evaluation showed negative antinuclear antibody, and anti-dsDNA, normal serum complements, an elevated MPO and positive anti GBM. She was treated with plasmapheresis and cyclophosphamide. Conclusion SARS-CoV-2 infection can be a 'trigger factor' for vasculitis. ANCA-associated vasculitis should be kept in mind in patients who develop acute kidney injury after COVID-19." @default.
• W4380447898 created "2023-06-14" @default.
• W4380447898 creator A5020153060 @default.
• W4380447898 creator A5020361708 @default.
• W4380447898 creator A5031154477 @default.
• W4380447898 creator A5057805029 @default.
• W4380447898 creator A5069090585 @default.
• W4380447898 creator A5081551288 @default.
• W4380447898 creator A5087433541 @default.
• W4380447898 date "2023-06-01" @default.
• W4380447898 modified "2023-09-24" @default.
• W4380447898 title "#5034 ANCA ASSOCIATED VASCULITIS AFTER COVID-19" @default.
• W4380447898 doi "https://doi.org/10.1093/ndt/gfad063d_5034" @default.
• W4380447898 hasPublicationYear "2023" @default.
• W4380447898 type Work @default.
• W4380447898 citedByCount "0" @default.
• W4380447898 crossrefType "journal-article" @default.
• W4380447898 hasAuthorship W4380447898A5020153060 @default.
• W4380447898 hasAuthorship W4380447898A5020361708 @default.
• W4380447898 hasAuthorship W4380447898A5031154477 @default.
• W4380447898 hasAuthorship W4380447898A5057805029 @default.
• W4380447898 hasAuthorship W4380447898A5069090585 @default.
• W4380447898 hasAuthorship W4380447898A5081551288 @default.
• W4380447898 hasAuthorship W4380447898A5087433541 @default.
• W4380447898 hasBestOaLocation W43804478981 @default.
• W4380447898 hasConcept C126322002 @default.
• W4380447898 hasConcept C142724271 @default.
• W4380447898 hasConcept C159654299 @default.
• W4380447898 hasConcept C203014093 @default.
• W4380447898 hasConcept C2776015282 @default.
• W4380447898 hasConcept C2778063415 @default.
• W4380447898 hasConcept C2778842783 @default.
• W4380447898 hasConcept C2778910314 @default.
• W4380447898 hasConcept C2779134260 @default.
• W4380447898 hasConcept C2779758542 @default.
• W4380447898 hasConcept C2780472472 @default.
• W4380447898 hasConcept C2781229154 @default.
• W4380447898 hasConcept C71924100 @default.
• W4380447898 hasConcept C90924648 @default.
• W4380447898 hasConceptScore W4380447898C126322002 @default.
• W4380447898 hasConceptScore W4380447898C142724271 @default.
• W4380447898 hasConceptScore W4380447898C159654299 @default.
• W4380447898 hasConceptScore W4380447898C203014093 @default.
• W4380447898 hasConceptScore W4380447898C2776015282 @default.
• W4380447898 hasConceptScore W4380447898C2778063415 @default.
• W4380447898 hasConceptScore W4380447898C2778842783 @default.
• W4380447898 hasConceptScore W4380447898C2778910314 @default.
• W4380447898 hasConceptScore W4380447898C2779134260 @default.
• W4380447898 hasConceptScore W4380447898C2779758542 @default.
• W4380447898 hasConceptScore W4380447898C2780472472 @default.
• W4380447898 hasConceptScore W4380447898C2781229154 @default.
• W4380447898 hasConceptScore W4380447898C71924100 @default.
• W4380447898 hasConceptScore W4380447898C90924648 @default.
• W4380447898 hasIssue "Supplement_1" @default.
• W4380447898 hasLocation W43804478981 @default.
• W4380447898 hasOpenAccess W4380447898 @default.
• W4380447898 hasPrimaryLocation W43804478981 @default.
• W4380447898 hasRelatedWork W1912084238 @default.
• W4380447898 hasRelatedWork W2015359949 @default.
• W4380447898 hasRelatedWork W2313329957 @default.
• W4380447898 hasRelatedWork W2583153491 @default.
• W4380447898 hasRelatedWork W2626700937 @default.
• W4380447898 hasRelatedWork W2897514451 @default.
• W4380447898 hasRelatedWork W2995206298 @default.
• W4380447898 hasRelatedWork W3091214191 @default.
• W4380447898 hasRelatedWork W4254435911 @default.
• W4380447898 hasRelatedWork W4385383013 @default.
• W4380447898 hasVolume "38" @default.
• W4380447898 isParatext "false" @default.
• W4380447898 isRetracted "false" @default.
• W4380447898 workType "article" @default.